Loading
EP0031 is an experimental small-molecule drug from Ellipses Pharma in phase 2 trials for non-small-cell lung cancer, aimed at RET.
EP0031 is a small-molecule drug developed by Ellipses Pharma. Its target is RET (the sponsor names RET). ClinicalTrials.gov describes the intervention as: EP0031 is a potent next-generation selective RET-inhibitor (SRI). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT05443126, plans to enrol 265 participants with primary completion expected 2027-03. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Small-molecule drug directed at RET, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to RET.
1.EP0031 slips into a pocket on RET.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"EP0031" OR ABSTRACT:"EP0031") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EP0031, not a curated reading list.
Shares RET, Non-small-cell lung cancer and the tag pipeline.
Shares Ellipses Pharma and the tag pipeline.
Shares Ellipses Pharma and the tag pipeline.
Shares Ellipses Pharma and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.